The effects of nebivolol on weight in individuals with hypertension

Traditional non-vasodilatory β-blockers (eg, atenolol, metoprolol, propanolol)–a commonly utilized class of medications for cardiovascular diseases including hypertension–are associated with a high incidence of adverse events, including significant weight gain (ranging up to 3.5 kg) which occurs within the first few months of treatment. Treatment with the third generation vasodilatory β1-selective antagonist/β3 agonist, nebivolol, does not appear to affect body weight or other metabolic parameters.
Source: Journal of the American Society of Hypertension - Category: Cardiology Authors: Tags: Obesity and Hypertension Source Type: research